This phenotype seems to be conserved during the carcinogenesis process and thus is an important tool to study breast cancer progression, however, it is limited by the great cellular heterogeneity of the CD44+/CD24-/low/lin-population, which probably does not contain solely bona fide CSCs. This evidence concerns the gene CD44 and breast carcinoma.